Jacobson Pharma Corp Ltd
Company Profile
Business description
Jacobson Pharma Corp Ltd and its subsidiaries are principally engaged in the development, production, marketing, and sale of essential medicines and specialty drugs to both the public and private sectors. The Group's essential medicines portfolio covers various therapeutic categories such as cardiovascular, central nervous system, gastrointestinal, antidiabetic, respiratory, anti-infective, etc.; and the specialty drugs portfolio comprises biosimilars, oncology medications, and orphan drugs. Additionally, its veterinary health division supports veterinarians and veterinary clinics with several products in different therapeutic classes and pharmaceutical forms. Geographically, the Group derives maximum revenue from Hong Kong, and the rest from Macau, the Chinese Mainland, and other regions.
Contact
388 Kwun Tong Road
Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1
Kwun Tong, Kowloon
Hong Kong
HKGT: +852 22672298
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
1,768
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |